Multiple myeloma in Korea: Past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

International Journal of Hematology

Volumn 92, Issue 1, 2010, Pages 52-57

  Lee, Jae Hoon ^a   Lee, Dong Soon ^b   Lee, Je Jung ^c   Chang, Yoon Hwan ^d   Jin, Jong Youl ^e   Jo, Deog Yeon ^f   Bang, Soo Mee ^g   Kim, Hyo Jung ^h   Kim, Jin Seok ⁱ   Kim, Kihyun ^j   Eom, Hyeon Seok ^k   Min, Chang Ki ^l   Yoon, Sung Soo ^b   Kim, Sun Hee ^j   Suh, Cheolwon ^m   Cho, Kyung Sam ⁿ  

^a Gachon University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Chonnam National University   (South Korea)

^d Korea Cancer Center Hospital   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Seoul National University Bundang Hospital   (South Korea)

^h Hallym University   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j Sungkyunkwan University   (South Korea)

^k National Cancer Center   (South Korea)

^l The Catholic University of Korea   (South Korea)

^m Asan Medical Center   (South Korea)

ⁿ Kyung Hee University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6 RECEPTOR; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

AGING; AIR POLLUTION; ARTICLE; ASIAN; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUCASIAN; CYTOGENETICS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ETHNIC DIFFERENCE; EVENT FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GENETIC POLYMORPHISM; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; INCIDENCE; KOREA; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; MULTIPLE MYELOMA; REPUBLIC OF KOREA;

EID: 77955171366     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0617-6     Document Type: Article

References (52)

1. H Lee M Lee 1959 A case of alpha2 plasmacytoma New Med J 2 1113 1117
2. SH Yang TY Kim BK Kim YW Koh DS Kwak NK Kim, et al. 1995 A statistical study of multiple myeloma in Korea Korean J Hematol 30 345 361
3. Annual report of the Korea Central Cancer Registry. Korea Central Cancer Registry, Ministry of Health and Welfare Republic of Korea. 2007. http://www.ncc.re.kr/.
4. Korean Health Insurance Review Agency. 2008 health insurance review and evaluation statistical yearbook. 2008. http://www.hira.or.kr/.
5. JH Lee SM Bang 2006 Epidemiological changes of multiple myeloma in Korea Korean J Hematol 41 225 234 10.5045/kjh.2006.41.4.225
6. DY Kang DI Lee KH Kim DJ Kim BS Kim SI Kim, et al. 1972 Statistical studies on multiple myeloma in Korea-preliminary report Korean J Hematol 7 31 40
7. HJ Kim DS Heo YJ Bang SJ Lee DH Choi S Park, et al. 1984 Multiple myeloma in Korea-clinical analysis and treatment results in 61 cases Korean J Int Med 28 770 778
8. TY Kim DS Heo YJ Bang S Park BK Kim NK Kim, et al. 1993 Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma Korean J Int Med 45 1 12
9. HJ Kim CI Seo KC Park HT Kim DS Heo YJ Bang, et al. 1992 Combination chemotherapy for the treatment of multiple myeloma J Korean Cancer Assoc 24 577 585
10. JW Jung JH Kim SY Kim HJ Yoon KS Cho 1995 A clinical study on multiple myeloma J Korean Cancer Assoc 27 869 878
11. JT Lee IH Kim JS Ahn KH Lee TY Kim YI Park, et al. 1996 Phase II trial of VAD (vincristine, doxorubicin, and dexamethasone) in refractory multiple myeloma Korean J Hematol 31 145 153 1:CAS:528:DyaK28Xlt1Wlur8%3D
12. EJ Lee KH Lee MS Hyun 1997 Clinical characteristics and therapeutic results in multiple myeloma Korean J Hematol 32 409 418
13. SW Kim BY Ryoo TY Kim YH Im YH Park BS Kim, et al. 1999 A phase II trial of VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for previously untreated multiple myeloma Korean J Int Med 56 75 84
14. JH Lee SM Bang S Lee HS Kim JS Ahn EK Cho, et al. 1999 High dose chemotherapy with autologous stem cell transplantation in multiple myeloma Korean J of Hematol 34 306 316 1:CAS:528:DyaK1MXjtV2gtbs%3D
15. SM Bang JH Lee SS Yoon JM Seong KS Cho YG Kang, et al. 2003 High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma J Korean Med Sci 18 673 678 14555819
16. Bang SM, Lee JH, Yoon SS, Park S, Lee JJ, Kim HJ, Jo DY, et al. Preliminary report of risk-based approach in Korean patients with newly diagnosed multiple myeloma. Blood. 2004;104:4911.
17. HS Oh JH Lee MJ Ahn CW Chung SI Lee Q Park, et al. 2002 Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial Int J Hematol 76 465 470 10.1007/BF02982813 12512842
18. KW Lee T Yun EK Song II Na H Shin SM Bang, et al. 2005 A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma J Korean Med Sci 20 598 602 10.3346/jkms.2005.20.4.598 1:CAS:528:DC%2BD2MXhtVGiu73F 16100450
19. DY Kim SA Im CM Seong SN Lee JH Lee SM Bang, et al. 2002 Salvage therapy with thalidomide in patients with multiple myeloma Korean J Hematol 37 259 264
20. SM Bang JH Lee SS Yoon S Park CK Min CC Kim, et al. 2006 A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma Int J Hematol 83 309 313 10.1532/IJH97.A30512 1:CAS:528:DC%2BD28XmtFOrurs%3D 16757429
21. H Kim HJ Sohn S Kim K Kim JH Lee SM Bang, et al. 2006 New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy Biol Blood Marrow Transplant 12 837 844 10.1016/j.bbmt.2006.04.006 16864054
22. SM Bang YR Kim HI Cho HS Chi EJ Seo CK Park, et al. 2006 Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma Cancer Genet Cytogenet 168 124 132 10.1016/j.cancergencyto.2006.02.015 1:CAS:528: DC%2BD28XmslyktLY%3D 16843102
23. Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, et al. Bortezomib, doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): preliminary analysis of efficacy and safety. the Korean Multiple Myeloma Working Party (KMMWP). Ann Hematol. 2010 [Epub ahead of print] (English).
24. YK Kim SK Sohn JH Lee DH Yang JH Moon JS Ahn, et al. 2010 Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study Ann Hematol 89 475 482 10.1007/s00277-009-0856-x 1:CAS:528:DC%2BC3cXjtlagsrw%3D 19921192
25. ®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: interim results of phase II trial. The Korean Multiple Myeloma Working Party (KMMWP). Blood. 2007;110:952 (ASH Annual Meeting Abstracts).
26. DH Yang YK Kim SK Sohn JS Chung YD Joo JH Lee, et al. 2010 Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study Clin Lymphoma Myeloma Leuk 10 62 67 10.3816/CLML.2010.n.007 1:CAS:528:DC%2BC3cXjvF2htLg%3D 20223731
27. HS Eom YK Kim JS Chung K Kim HJ Kim HY Kim, et al. 2010 Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) Ann Hematol 89 489 497 10.1007/s00277-009-0871-y 1:CAS:528:DC%2BC3cXjtlahu7Y%3D 20012045
28. SH Kang TY Kim HY Kim YK Lee HW Moon DS Lee, et al. 2006 Association of NQO1 polymorphism with multiple myeloma risk in Korea Korean J Lab Med 26 71 76 10.3343/kjlm.2006.26.2.71 1:CAS:528:DC%2BD28XlvFaku7s%3D 18156703
29. SH Kang TY Kim HY Kim JH Yoon HI Cho SS Yoon, et al. 2008 Protective Role of CYP1A1*2A in the development of multiple myeloma Acta Hematol 119 60 64 10.1159/000117572 1:CAS:528:DC%2BD1cXjtVChtr0%3D
30. TY Kim J Park B Oh HJ Min TS Jeong JH Lee, et al. 2009 Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction Br J Haematol 146 270 281 10.1111/j.1365-2141.2009.07752.x 1:CAS:528:DC%2BD1MXhtValurrK 19500098
31. Min HJ, Kim TY, Oh B, Lee JH, Lee DS. The assessment of IL-6R gene using FISH in MM. Blood. 2007;110:4849 (ASH Annual Meeting Abstracts).
32. Kang SH, Lee DS, Kim TY, Min HJ, Oh B, Cho HI, et al. Methylation profiles of p16, p15 and p14 genes in Korean patients with multiple myeloma. Blood. 2007;110:1504 (ASH Annual Meeting Abstracts).
33. SJ Kim K Kim BS Kim DY Jo HJ Kang JS Kim, et al. 2009 Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry Acta Hematol 122 200 210 10.1159/000253027
34. JS Kim K Kim JW Cheong YH Min C Suh H Kim, et al. 2009 Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation Biol Blood Marrow Transplant 15 463 470 10.1016/j.bbmt.2008.12. 512 1:CAS:528:DC%2BD1MXkslKhur0%3D 19285634
35. Min CK, Kim H, Kim K, Kwak JY, Lee ST, Won JH, et al. A multicenter comparison of autologous stem cell transplantation followed by reduced-intensity allogeneic stem cell transplantation with tandem autologous stem cell transplantation in multiple myeloma. Blood. 2007;110:940 (ASH Annual Meeting Abstracts).
36. Sym SJ, Kwak JY, Min CK, Won JH, Lee ST, Kim K, et al. Single and tandem autologous peripheral blood stem cell transplantation for patients with multiple myeloma: a korean multicenter retrospective study. Blood. 2007;110:5132 (ASH Annual Meeting Abstracts).
37. SJ Kim K Kim BS Kim HJ Lee H Kim NR Lee, et al. 2008 Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma Clin Lymphoma Myeloma Leuk 8 237 240 10.3816/CLM.2008.n.031 1:CAS:528: DC%2BD1cXhtlClur%2FO
38. Y Koh SM Bang JH Lee HJ Yoon YR Do HM Ryoo, et al. 2010 Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide Ann Hematol 89 201 206 10.1007/s00277-009-0807-6 1:CAS:528:DC%2BC3cXjt1yksA%3D%3D 19705118
39. Kim SJ, Kim K, Lee JH, Kim MK, Kwak JY, Ryoo HM, et al. Bortezomib-based induction therapy induces better responses and outcomes of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: the results of Korean Multiple Myeloma Working Party retrospective study, KMM84. Blood. 2008;112:5184.
40. SM Bang JW Seo KU Park SJ Kim K Kim SH Kim, et al. 2010 Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia Cancer Genet Cytogenet 197 117 121 10.1016/j.cancergencyto.2009.11.008 1:CAS:528:DC%2BC3cXisFarsbY%3D 20193844
41. JJ Lee BH Choi HK Kang MS Park JS Park SK Kim, et al. 2007 Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates Leuk Lymphoma 48 2022 2031 10.1080/10428190701583975 1:CAS:528:DC%2BD2sXhtFeitbvF 17917970
42. SK Kim TN Nguyen Pham TM Nguyen Hoang HK Kang CJ Jin JH Nam, et al. 2009 Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens Ann Hematol 88 1113 1123 10.1007/s00277-009-0721-y 1:CAS:528:DC%2BD1MXhtFCju7rE 19277657
43. DH Yang JS Park CJ Jin HK Kang JH Nam JH Rhee, et al. 2009 The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma Leuk Res 33 665 670 10.1016/j.leukres.2008.09.006 1:CAS:528:DC%2BD1MXivVWqu7Y%3D 18922577
44. Yang DH, Kim MH, Hong CY, Lee YK, Jin CJ, Pham TN, et al. Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells. Ann Hematol. 2010 [Epub ahead of print].
45. Kim MK, Suh C, Min CK, Kim JS, Kim K, Moon JH, et al. Immunoglobulin D multiple myeloma: clinical presentation, response to therapy and prognostic factors in 75 patients: an analysis of the Korean Multiple Myeloma Working Party (KMMWP). Blood. 2009;114:1792 (ASH Annual Meeting Abstracts).
46. Kim HJ, Choi DR, Yun GW, Park EK, Kim SJ, Lee YK, et al. Myelomatous pleural effusion of multiple myeloma: characteristics and outcome. Blood. 2009;114:3874 (ASH Annual Meeting Abstracts).
47. Kim HJ, Shim H, Park EK, Kim MK, Kim SJ, Park JS, et al. Osteonecrosis of the jaw in multiple myeloma patients: incidence and characteristics in Korean patients. Blood. 2009;114:4956 (ASH Annual Meeting Abstracts).
48. Kim MJ, Oh SJ, Min CK, Park CW, Yoon HJ, Do YR, et al. The prognostic impact of fluorescent-in situ hybridization (FISH) and conventional karyotyping in Korean multiple myeloma patients: a retrospective multicenter study. Blood. 2009;114:4902 (ASH Annual Meeting Abstracts).
49. Min CK, Kim SJ, Lee JJ, Suh C, Kim JS, Yoon SS, et al. The effect of bortezomib on bone metabolism of patients with multiple myeloma: a Korean multicenter prospective study. Blood. 2009;114:4871 (ASH Annual Meeting Abstracts).
50. Avet-Loiseau H, Durie BGM, Haessler J, Crowley J, Hoering A, Barlogie B, et al. Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients. Blood. 2009;114:743 (ASH Annual Meeting Abstracts).
51. Kumar S, Crowley J, Goldschmidt H, Hoering A, Jagannath S, Lahuerta JJ, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study. Blood. 2009;114:2878 (ASH Annual Meeting Abstracts).
52. A Palumbo O Sezer R Kyle JS Miguel RZ Orlowski P Moreau, et al. 2009 International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation Leukemia 23 1716 1730 10.1038/leu.2009.122 1:STN:280:DC%2BD1Mnos12jtA%3D%3D 19494840